Protocol Library - Altai Oncology Software

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions

Over 1,000 cancer treatment protocols

Medical Oncology, Hematology, Bone Marrow Transplantation

With administration details, lab parameters, indications, and summarized references

Updated monthly to include latest approvals and major papers

Reviewed by Medical Oncologists and Hematologists

Melanoma

New Protocol: Atezolizumab with Vemurafenib and Cobimetinib in Metastatic Melanoma

Ulas D. Bayraktar, MD

Ovarian Cancer

New Drug: Mirvetuximab Soravtansine in FRalpha Positive Ovarian Cancer

Ulas D. Bayraktar, MD

Acute myeloid leukemia

New Drug: Enasidenib in IDH2 Mutant AML

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Indication: Durvalumab with Tremelimumab in Metastatic NSCLC

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Protocol: Cemiplimab with Chemotherapy in NSCLC

Ulas D. Bayraktar, MD

Follicular Lymphoma

New Drug: Mosunetuzumab for R/R Follicular Lymphoma

Ulas D. Bayraktar, MD

Breast Cancer

New Protocol: Pembrolizumab with Chemotherapy in Triple-Negative Breast Cancer

Ulas D. Bayraktar, MD

Nervous System Tumor Thyroid Cancer

New Indication: Dabrafenib and Trametinib in bRAV V600E Mutant Anaplastic Thyroid Cancer

Ulas D. Bayraktar, MD

Acute myeloid leukemia

New Protocol: Venetoclax with 3 + 7 Chemotherapy for AML

Ulas D. Bayraktar, MD

New Protocol: Atezolizumab with Vemurafenib and Cobimetinib in Metastatic Melanoma

Phase III, multicenter, randomized, double-blind trial Previously untreated unresectable stage IIIc or stage IV melanoma Atezolizumab (n=256) vs. PBO + vemurafenib + cobiventinib (

New Drug: Mirvetuximab Soravtansine in FRalpha Positive Ovarian Cancer

Single-arm, Phase-3 trial (SONAYA) Platinum-resistant epithelial ovarian cancer (up to three prior lines of systemic therapy; all patients were required to have received bevacizuma

Acute myeloid leukemia

New Drug: Enasidenib in IDH2 Mutant AML

Phase III, randomized, open-label study Patients aged ≥60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R) to 2 or 3 prior AML-directed t

Non-Small Cell Lung Cancer

New Indication: Durvalumab with Tremelimumab in Metastatic NSCLC

Phase III, randomized, three-arm, open-label study (POSEIDON) Previously untreated mNSCLC Arm A: (T+C+CT) Tremelimumab 75 mg plus durvalumab 1,500 mg and chemotherapy for up to fou

Non-Small Cell Lung Cancer

New Protocol: Cemiplimab with Chemotherapy in NSCLC

Double-blind, placebo-controlled, phase 3 study Untreated advanced or metastatic NSCLC Group A (Cemiplimab + chemotherapy (n=312)) vs. group B (chemotherapy alone (n=154))

Follicular Lymphoma

New Drug: Mosunetuzumab for R/R Follicular Lymphoma

Single-arm, multicenter, phase 2 study Relapsed or refractory to two or more previous lines of treatment Mosunetuzumab q21 days (n=90)

New Protocol: Pembrolizumab with Chemotherapy in Triple-Negative Breast Cancer

Phase 3, randomized, double-blind, international trial Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer Pembrolizumab (200 mg every 3 w

Nervous System TumorThyroid Cancer

New Indication: Dabrafenib and Trametinib in bRAV V600E Mutant Anaplastic Thyroid Cancer

Open-label, nonrandomized, phase II basket study Unresectable or metastatic 36 anaplastic thyroid cancer patients Dabrafenib 150 mg x 2 /day plus trametinib 2 mg/day

Acute myeloid leukemia

New Protocol: Venetoclax with 3 + 7 Chemotherapy for AML

Two-stage, single-arm, phase 2 trial Previously untreated de novo acute myeloid leukaemia IV daunorubicin (60 mg/m2 on days 1-3), IV cytarabine (100 mg/m2 on days 1-7), and oral ve

Our Solutions

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols

Altai Oncology Suite

Our premiere, CE-marked, Windows application designed for cancer centers

Altai Oncology App

Easiest access to our protocol library on your hands

Altai Chemo Planner

Core features of Altai Oncology Suite for the solo Oncologist/Hematologist

Articles

Computerized Chemotherapy Order Entry

The Power of a Protocol Library: Standardizing Oncology Care Across Institutions

Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …

From Protocol to Pharmacy: Ensuring Seamless Chemotherapy Order Handover

Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.

Back to top Drag